Ubiquitination signature identified in neuroendocrine prostate cancer with therapeutic implications
A ubiquitination-centered signature linked to neuroendocrine prostate cancer (NEPC) was identified, highlighting its role in lineage plasticity.
Asset / Drug
Drug and asset intelligence for Ubiquitination with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.